Recent cumulative evidence has pointed out that multiple immune checkpoints expressed by tumor cells play crucial roles in tumor immune evasion, among which PD-L1/PD-1 is regarded as a pivotal pair of valuable therapeutic targets. Here, CD274 is linked to neoplasm.